12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Allos, Spectrum Pharmaceuticals deal

Spectrum extended to 5 p.m. EDT on Aug. 20 from Aug. 6 its tender offer to acquire cancer company Allos for $1.82 per share in cash. Spectrum said it extended the offer to "continue cooperating" with a May request from the U.S. Federal Trade Commission...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >